Filler Pricing & Margin Guide: Juvéderm, Restylane, RHA, Radiesse

Your cost per syringe is the floor. AbbVie (Allergan Aesthetics), Galderma, and Revance all operate tiered rebate and loyalty programs—Alle (AbbVie), Aspire (Galderma), and Evolus Rewards—that reward volume and mix commitments. A practice buying 50 syringes/month of Juvéderm Ultra Plus XC at standard wholesale (roughly $110–130 per syringe, depending on distributor and region) may qualify for 5–10% rebates if committed to minimum quarterly volume; a 200+ syringe/month practice can negotiate 12–18% off list. Radiesse (Galderma) and RHA (Revance) command slightly higher wholesale ($135–160 and $140–165 respectively) because they occupy premium positioning and have lower market penetration than Juvéderm. Restylane (Galderma) sits in the middle. Biostimulators—Sculptra PLLA and Radiesse CaHA—carry the highest per-unit cost but deliver longer duration (12–24 months vs. 6–12 for HA), which affects patient lifetime value and repeat-visit frequency. Track your actual landed cost (including freight, storage, and spoilage) and negotiate rebates annually; most practices underestimate their true cost by 3–5% because they don't account for waste or distributor fees.

Cash pricing for a single syringe of premium HA (Juvéderm Ultra Plus XC, Restylane Lyft) ranges from $600–$900 in major metros; RHA and Radiesse command $700–$1,000 because of their rheology and duration claims. Biostimulators (Sculptra, Radiesse CaHA) run $800–$1,200 per syringe. These are not fixed; they reflect local competition, your brand positioning, and patient demographics. A practice in a high-income zip code with strong brand recognition and minimal direct competition can price at the top of the range; a practice in a saturated market or with lower brand equity must price lower. Insurance rarely covers filler—it is almost entirely cash. This means your pricing power is constrained only by patient willingness to pay and competitor pricing, not by contracted rates. However, practices that bundle fillers into package deals (e.g., "full face" for $2,500 including lips, cheeks, and tear troughs) often discount per-syringe equivalent by 10–15% to drive volume and patient lifetime value. Track your actual realized price per syringe across all payment types; many practices quote high but realize 15–20% lower due to discounting, package deals, and patient negotiation.

Margin is not syringe-agnostic. A single syringe of Juvéderm Ultra Plus XC placed in the lips (0.5–1 syringe, 30–45 minutes) at $700 retail and $120 cost yields ~$580 gross margin on 0.75 syringe = $773 per syringe margin, or 77% gross margin. The same syringe in cheek augmentation (1–2 syringes, 20–30 minutes) at $800 retail and $120 cost yields $680 per syringe margin, or 85% gross margin. Tear trough filler (0.5 syringe, 15 minutes) at $400 retail and $120 cost yields $560 per syringe margin, or 80% gross margin. The variance reflects patient tolerance for volume, anatomic constraints, and time efficiency. Lips and tear troughs are high-margin per-minute because they require small volumes and command premium pricing; full-face volumization (cheeks, temples, jawline, 3–4 syringes) is lower margin per syringe but higher total margin per appointment and drives patient satisfaction and retention. Practices that excel at strategic placement (using less product to achieve results) and upselling complementary treatments (neuromodulator + filler, or filler + RF microneedling) extract 60–70% blended gross margin across the filler portfolio.

Sculptra PLLA and Radiesse CaHA are not margin plays on the first treatment; they are patient lifetime value plays. A single Sculptra treatment (typically 3–4 syringes over 3 sessions, spaced 4–6 weeks) costs the practice $360–480 and retails for $2,400–$3,600, yielding 40–50% gross margin per syringe—lower than HA. However, Sculptra lasts 12–24 months (vs. 6–9 months for HA), so a patient who returns annually for HA filler instead returns every 18–24 months for Sculptra maintenance. Over 3 years, the HA patient generates 4–6 filler visits; the Sculptra patient generates 1–2 Sculptra visits plus 2–3 HA touch-ups or complementary treatments. The blended margin over patient lifetime is higher for Sculptra, and the patient is less price-sensitive because they perceive better value and longer duration. Radiesse CaHA (12–18 month duration) sits between HA and PLLA; it commands higher per-syringe pricing ($900–$1,200) and lower per-syringe cost ($130–160) than Sculptra, yielding 60–70% gross margin and a 12–18 month interval. Practices that build a biostimulator-forward protocol (educating patients on duration and value) achieve higher average transaction value and lower patient acquisition cost per dollar of revenue.

Most practices quote retail cash pricing but realize 10–25% less due to discounting, package deals, and patient negotiation. A practice quoting $750/syringe for Juvéderm Ultra Plus XC may realize $625–675 after accounting for: 15% of patients negotiating down, 20% of patients buying packages (3+ syringes at 10% discount), and 5% of patients using financing (which reduces effective price by 2–3% due to processing fees). This erosion is normal and reflects market dynamics; practices that maintain 85%+ of quoted price typically have strong brand positioning, limited local competition, or a high-income patient base. Track your realized price per syringe monthly, not just quoted price. If realized price is more than 15% below quoted price, either your quoting is misaligned with market, your discounting is too aggressive, or your patient mix is shifting downmarket. Practices in saturated markets or with weak brand positioning often operate at 60–70% of quoted price; practices with strong positioning and limited competition operate at 90–95%.

Filler pricing is local. A Juvéderm Ultra Plus XC syringe priced at $650 in a secondary market may be $850 in Manhattan or Los Angeles. Use RealSelf, Zocdoc, and local competitor mystery shopping to calibrate your pricing quarterly. If you are 20%+ above local average, you are likely losing price-sensitive patients; if you are 20%+ below, you may be leaving margin on the table or signaling lower quality. Most practices price within 10% of local competitors. Differentiation comes from outcomes, speed, and patient experience, not price—a practice that consistently delivers natural results, books quickly, and has strong patient reviews can command 10–15% premium pricing. Practices competing on price alone typically operate at 50–60% gross margin and struggle with volume efficiency. Consider your positioning: are you a high-volume, efficient operator (targeting 65–70% gross margin and high patient throughput), or a premium, outcomes-focused practice (targeting 75–80% gross margin and lower volume)? Your pricing strategy should align with your positioning and your cost structure.

Filler is high-margin but labor-intensive. A single syringe of Juvéderm Ultra Plus XC at $750 retail, $120 cost, and 30 minutes of provider time (assuming $200/hour blended provider cost including overhead) yields: $750 revenue – $120 cost – $100 provider labor = $530 contribution margin, or 71% gross margin. However, this does not account for facility overhead (rent, utilities, staff, equipment), which typically runs 25–35% of revenue in a medical practice. After overhead, your net margin is 36–46% on filler. This means you need to sell 2–3 syringes per hour to achieve 50%+ net margin. Practices that bundle filler with neuromodulator (Botox, Dysport) or energy-based treatments (RF microneedling, laser) increase per-appointment revenue and overhead absorption, lifting net margin to 50–60%. Track your filler volume per hour and per provider monthly; if you are below 1.5 syringes/hour, your protocol or scheduling is inefficient. If you are above 3 syringes/hour, you may be sacrificing quality or patient safety.

Filler margin is 60–80% gross, but realized price is 10–25% below quoted price, and net margin after overhead is 35–50%. Biostimulators trade lower per-syringe margin for higher patient lifetime value and less price sensitivity. Acquisition cost varies 15–30% based on volume and loyalty program participation; negotiate annually. Price locally, not nationally, and differentiate on outcomes and experience, not price alone. Track realized price per syringe, margin per area, and volume per hour monthly to identify optimization opportunities.